Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.

This randomized, multicenter, double-blind study was designed to compare specifically the onset of antidepressant action of mirtazapine orally disintegrating tablets (ODT) with venlafaxine extended-release (XR) formulation in outpatients with major depression. Both treatments were administered in a rapidly escalating dosing regimen. Target doses (mirtazapine ODT, 45 mg OD; venlafaxine XR, 225 mg OD) were reached by day 6 of treatment.

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.

Study Objectives: To assess the safety and efficacy of cabergoline in the treatment of idiopathic restless legs syndrome (RLS) patients.

Design: Open-label intervention study for 26 weeks; no control group.

Setting: 302 patients (73% women, aged 61 +/- 11 years) from 37 German neurologic outpatient departments and private practices.